SEC Form 4 · accession 0001140361-16-063350
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Robert Ajer
Officer — EVP, Chief Commercial Officer
Period of report
Apr 29, 2016
Accepted (ET)
May 4, 2016 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 29, 2016 | A | 415 | $51.264 | A | 63,487 | D | |
| Common StockF2,F3 | May 3, 2016 | S | 415 | $86.0259 | D | 63,072 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person is reporting the purchase of shares of the issuer's Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2015 to April 30, 2016.
- F2Transaction made pursuant to a Rule 10b5-1 trading plan executed on May 11, 2015.
- F3The price in column 4 is a weighted average price. The price actually received ranged from $85.32 to $86.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range